MLN2480 is a potent and selective inhibitor of the Aurora A kinase enzyme, which plays a critical role in cell cycle regulation, particularly in mitotic spindle formation and centrosome function. Due to its mechanism of action, MLN2480 has been investigated primarily in oncology for the treatment of various solid tumors and hematologic malignancies. It disrupts abnormal cell division in cancer cells, leading to cell cycle arrest and apoptosis. The compound has shown promising antitumor activity in preclinical models, especially in cancers with dysregulated Aurora A signaling, such as neuroblastoma, non-small cell lung cancer, and certain types of leukemia. It is also being studied for its potential to overcome resistance to other chemotherapeutic agents when used in combination therapies. Because of its targeted action, MLN2480 offers a strategy to minimize damage to normal, healthy cells—potentially reducing side effects commonly associated with traditional chemotherapy. Clinical development has focused on determining optimal dosing, safety, and efficacy in early-phase trials, with ongoing research exploring biomarkers to identify responsive patient populations.